Aspect Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Aspect Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$13.6K	Buy	26 +5	+24%	+$2.56K	0.01%	238
2026 Q2	$10.4K	Hold	21	–	–	﹤0.01%	276
2026 Q1	$9.38K	Hold	21	–	–	﹤0.01%	273
2025 Q4	$9.5K	Hold	21	–	–	﹤0.01%	279
2025 Q3	$8.22K	Sell	21 -1	-5%	-$418	﹤0.01%	332
2025 Q2	$9.8K	Sell	22 -2	-8%	-$922	﹤0.01%	286
2025 Q1	$11.6K	Buy	24 +2	+9%	+$932	0.01%	244
2024 Q4	$8.86K	Sell	22 -1	-4%	-$464	0.01%	300
2024 Q3	$10.7K	Hold	23	–	–	0.01%	261
2024 Q2	$10.8K	Sell	23 -7	-23%	-$3.04K	0.01%	255
2024 Q1	$12.5K	Hold	30	–	–	0.01%	247
2023 Q4	$12.2K	Buy	+30	New	+$11.1K	0.01%	239

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Provident Investment Management Novi, Michigan $999M AUM 19.45% 1-Year Est. Return

Aspect Partners's VRTX Position: Q3 2026 in Review

Aspect Partners increased its Vertex Pharmaceuticals (VRTX) stake by 24% in Q3 2026, buying an estimated $2.56K and bringing the position to 26 shares worth $13.6K. The position accounts for 0.01% of the portfolio, ranked #238.

Aspect Partners first reported a position in VRTX in Q4 2023 and has held it in 12 quarters since. 478 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Aspect Partners held 26 shares of Vertex Pharmaceuticals worth $13.6K as of Q3 2026.
Aspect Partners bought 5 Vertex Pharmaceuticals shares in Q3 2026, an estimated $2.56K.
Vertex Pharmaceuticals made up 0.01% of Aspect Partners's portfolio in Q3 2026, its #238 holding.
Aspect Partners first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
478 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Aspect Partners's 13F filing for Q3 2026, filed 20 Oct 2026.